{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:33:55Z","timestamp":1793799235448,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","award":["R23087HH"],"award-info":[{"award-number":["R23087HH"]}],"id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["ANR-23-RHUS-0014"],"award-info":[{"award-number":["ANR-23-RHUS-0014"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["847949"],"award-info":[{"award-number":["847949"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-CE14-0006-01"],"award-info":[{"award-number":["ANR-18-CE14-0006-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["I003420N"],"award-info":[{"award-number":["I003420N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["I000123N"],"award-info":[{"award-number":["I000123N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1802154N"],"award-info":[{"award-number":["1802154N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016915","name":"Inventiva SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["FRM EQU202303016287"],"award-info":[{"award-number":["FRM EQU202303016287"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jhepr.2025.101366","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T11:35:47Z","timestamp":1740224147000},"page":"101366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9567-1859","authenticated-orcid":false,"given":"Pierre-Emmanuel","family":"Rautou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2333-302X","authenticated-orcid":false,"given":"Shivani","family":"Chotkoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1356-6543","authenticated-orcid":false,"given":"Louise","family":"Biquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Wettstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8179-6802","authenticated-orcid":false,"given":"Denise","family":"van der Graaff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"De Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Casteleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7080-3592","authenticated-orcid":false,"given":"Sofie","family":"Thys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0960-6781","authenticated-orcid":false,"given":"Winnok H.","family":"De Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bedossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3230-7591","authenticated-orcid":false,"given":"Michael P.","family":"Cooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Baudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Huot-Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucile","family":"Dzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7311-1623","authenticated-orcid":false,"given":"Miguel","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Broqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Junien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3999-9259","authenticated-orcid":false,"given":"Luisa","family":"Vonghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-8618","authenticated-orcid":false,"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9474-6695","authenticated-orcid":false,"given":"Wilhelmus J.","family":"Kwanten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Paradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven M.","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2025.101366_bib1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib2","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib3","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101366_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000913","article-title":"Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","author":"Qi","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101366_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib6","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2025.101366_bib7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","article-title":"Immune cell-mediated features of non-alcoholic steatohepatitis","volume":"22","author":"Huby","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhepr.2025.101366_bib8","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41575-023-00832-w","article-title":"Cellular stress in the pathogenesis of nonalcoholic steatohepatitis and liver fibrosis","volume":"20","author":"Sharma","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10620-017-4903-5","article-title":"Origins of portal hypertension in nonalcoholic fatty liver disease","volume":"63","author":"Baffy","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2025.101366_bib10","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ijo.2010.134","article-title":"Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension","volume":"35","author":"Francque","year":"2011","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jhepr.2025.101366_bib11","first-page":"1449","article-title":"Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis","volume":"22","author":"Francque","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib12","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jhep.2020.10.011","article-title":"Patients with NAFLD do not have severe portal hypertension in the absence of cirrhosis","volume":"74","author":"Moga","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib13","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of liver sinusoidal endothelial cells in nonalcoholic fatty liver disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.mehy.2018.11.014","article-title":"The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis","volume":"122","author":"van der Graaff","year":"2019","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.jhepr.2025.101366_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1478-3231.2009.02136.x","article-title":"Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model","volume":"30","author":"Francque","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101366_bib16","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/labinvest.2012.103","article-title":"Increased intrahepatic resistance in severe steatosis: endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture","volume":"92","author":"Francque","year":"2012","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhepr.2025.101366_bib17","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/s41374-017-0018-z","article-title":"Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats","volume":"98","author":"Van der Graaff","year":"2018","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhepr.2025.101366_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032785","article-title":"Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD","volume":"7","author":"Pasar\u00edn","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2025.101366_bib19","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.3748\/wjg.v23.i37.6777","article-title":"Intrahepatic vascular changes in non-alcoholic fatty liver disease: potential role of insulin-resistance and endothelial dysfunction","volume":"23","author":"Pasar\u00edn","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2025.101366_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41366-023-01443-w","article-title":"The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease","volume":"48","author":"Van Eyck","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jhepr.2025.101366_bib21","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s00428-023-03496-8","article-title":"Zonated quantification of immunohistochemistry in normal and steatotic livers","volume":"482","author":"Peleman","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jhepr.2025.101366_bib22","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2024.05.014","article-title":"Angiocrine signaling in sinusoidal homeostasis and liver diseases","volume":"81","author":"Gao","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib23","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/HEP.0000000000000207","article-title":"The evolving role of liver sinusoidal endothelial cells in liver health and disease","volume":"78","author":"McConnell","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101366_bib24","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/labinvest.2015.95","article-title":"Pivotal role of liver sinusoidal endothelial cells in NAFLD\/NASH progression","volume":"95","author":"Miyao","year":"2015","journal-title":"Lab Invest"},{"key":"10.1016\/j.jhepr.2025.101366_bib25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.30294","article-title":"Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease","volume":"69","author":"Lefere","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101366_bib26","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101366_bib27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cld.2015.10.011","article-title":"Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children","volume":"20","author":"Kleiner","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2025.101366_bib28","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101366_bib29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41575-024-00938-9","article-title":"Envisioning how to advance the MASH field","volume":"21","author":"Allen","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib30","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.14844","article-title":"New drugs for NASH","volume":"41","author":"Albhaisi","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2025.101366_bib31","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study","volume":"98","author":"Francque","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jhepr.2025.101366_bib32","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.jhep.2020.11.045","article-title":"Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","volume":"74","author":"Boyer-Diaz","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2025.101366_bib33","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2025.101366_bib34","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1038\/s41467-024-47919-9","article-title":"The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis","volume":"15","author":"Cooreman","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101366_bib35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5414\/NP300817","article-title":"ERG is a novel and reliable marker for endothelial cells in central nervous system tumors","volume":"34","author":"Haber","year":"2015","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.jhepr.2025.101366_bib36","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","article-title":"Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate","volume":"61","author":"Boubia","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhepr.2025.101366_bib37","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101366_bib38","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101366_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/srep44356","article-title":"Immunofluorescence identifies distinct subsets of endothelial cells in the human liver","volume":"7","author":"Strauss","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2025.101366_bib40","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1038\/s41467-018-06318-7","article-title":"Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations","volume":"9","author":"MacParland","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2025.101366_bib41","article-title":"Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD","volume":"4","author":"van der Graaff","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2025.101366_bib42","first-page":"543","article-title":"Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis","volume":"1","author":"Kitade","year":"2008","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jhepr.2025.101366_bib43","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2025.101366_bib44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/fca-2017-0019","article-title":"PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-\u03b2\/\u03b4 and PPAR-\u03b3","volume":"13","author":"Han","year":"2017","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jhepr.2025.101366_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2217\/fca-2016-0059","article-title":"PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-\u03b1","volume":"13","author":"Han","year":"2017","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jhepr.2025.101366_bib46","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/apt.17046","article-title":"Review article: vascular effects of PPARs in the context of NASH","volume":"56","author":"Guixe-Muntet","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2025.101366_bib47","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2025.101366_bib48","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"New Engl J Med"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925000436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555925000436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:11:48Z","timestamp":1762632708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555925000436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2589555925000436"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101366","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2025.101366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101366"}}